As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome. The deletion occurs near the middle of the chromosome at a location designated q11.2. It is considered a mid-line condition, with physical symptoms including characteristic palate abnormalities, heart defects, immune dysfunction, and esophageal / GI issues, as well as debilitating neuropsychiatric and behavioral challenges. Anxiety is among the most common neuropsychiatric symptoms of 22q and researchers have found that for children with 22q, anxiety is linked to poorer adaptive behaviors such as self-care and communication skills that affect daily life. Children with 22q also experience withdrawn behavior, ADHD, cognitive impairment, and autism spectrum disorder that affect communication and social interaction. Later in life, they are at an increased risk of developing mental illnesses such as schizophrenia.
It is estimated that 22q occurs in between one in 3,000 and one in 6,000 live births, suggesting that there are approximately 81,000 people living with 22q in the U.S.
There are currently no approved drugs for 22q!
Our Biotech company is developing the first and only pharmaceutically-manufactured CBD gel formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
With pharmaceutical grade CBD it may be possible to treat various neuropsychiatric symptoms of 22q:
- Agonist at serotonin 1A receptors
- Antagonist to GPR55 receptors
- Modulator of the endocannabinoid system
In the second quarter of 2019, our Biotech pearl initiated a clinical study on the use of the CBD gel in the use and treatment of neuropsychiatric symptoms at 22q. The first results are already expected in the first half of 2020!
Subscribe to our free newsletter now – with detailed information, market commentary, active traded model portfolio and trade signals to promising cannabis company.
After registering for our free newsletter, you will receive your password for the premium content area at: https://cannabisradar.de/premium-content/ and you can download all previous trade signals and former newsletter issues!
We can very well imagine that our new cannabinoid biotech gem will be able to evolve in a similar way to our sample pot value GW Pharmaceuticals!
GW Pharma has skyrocketed from $ 10 to $ 200 in just 6 years. GW Pharmaceuticals launched an FDA-approved drug (Epidiolex with CBD) in 2018 for the treatment of rare epileptic diseases.
We expect a similar success story of our biotech pick when the patented CBD gel is being approved by the FDA or another drug regulation authority for the treatment of various neuropsychiatric disorders!